Literature DB >> 22241682

Effect of dual inhibition of apoptosis and autophagy in prostate cancer.

Ahamed Saleem1, Dmitri Dvorzhinski, Urmila Santanam, Robin Mathew, Kevin Bray, Mark Stein, Eileen White, Robert S DiPaola.   

Abstract

PURPOSE: Targeting multiple anti-apoptotic proteins is now possible with the small molecule BH3 domain mimetics such as ABT-737. Given recent studies demonstrating that autophagy is a resistance mechanism to multiple therapeutic agents in the setting of apoptotic inhibition, we hypothesized that hydroxychloroquine (HCQ), an anti-malarial drug that inhibits autophagy, will increase cytotoxicity of ABT-737. EXPERIMENTAL
DESIGN: Cytotoxicity of ABT-737 and HCQ was assessed in vitro in PC-3 and LNCaP cells, and in vivo in a xenograft mouse model. The role of autophagy as a resistance mechanism was assessed by siRNA knockdown of the essential autophagy gene beclin1. ROS was measured by flow cytometry, and mitophagy assessed by the mCherry-Parkin reporter.
RESULTS: Induction of autophagy by ABT-737 was a mechanism of resistance in prostate cancer cell lines. Therapeutic inhibition of autophagy with HCQ increased cytotoxicity of ABT-737 both in vitro and in vivo. ABT-737 induced LC-3 and decreased p62 expression by immunoblot in cell lines and by immunohistochemistry in tumors in vivo. Assessment of ROS and mitochondria demonstrated that ROS production by ABT-737 and HCQ was a mechanism of cytotoxicity.
CONCLUSIONS: We demonstrated that autophagy inhibition with HCQ enhances ABT-737 cytotoxicity in vitro and in vivo, that LC-3 and p62 represent assessable markers in human tissue for future clinical trials, and that ROS induction is a mechanism of cytotoxicity. These results support a new paradigm of dual targeting of apoptosis and autophagy in future clinical studies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241682      PMCID: PMC3840901          DOI: 10.1002/pros.22487

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.

Authors:  Tateki Yoshino; Hiroaki Shiina; Shinji Urakami; Nobuyuki Kikuno; Tatsuaki Yoneda; Kazushi Shigeno; Mikio Igawa
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

3.  Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.

Authors:  Yuting Lin; Junichi Fukuchi; Richard A Hiipakka; John M Kokontis; Jialing Xiang
Journal:  Cell Res       Date:  2007-06       Impact factor: 25.617

4.  p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate.

Authors:  Yoshihisa Watanabe; Masaki Tanaka
Journal:  J Cell Sci       Date:  2011-07-19       Impact factor: 5.285

5.  Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy.

Authors:  Robert S DiPaola; Dmitri Dvorzhinski; Anu Thalasila; Venkata Garikapaty; Donyell Doram; Michael May; K Bray; Robin Mathew; Brian Beaudoin; C Karp; Mark Stein; David J Foran; Eileen White
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

Review 6.  The double-edged sword of autophagy modulation in cancer.

Authors:  Eileen White; Robert S DiPaola
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 7.  Mimicking the BH3 domain to kill cancer cells.

Authors:  T Ni Chonghaile; A Letai
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 8.  Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.

Authors:  Mark S Cragg; Claire Harris; Andreas Strasser; Clare L Scott
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

9.  Autophagy suppresses tumorigenesis through elimination of p62.

Authors:  Robin Mathew; Cristina M Karp; Brian Beaudoin; Nhan Vuong; Guanghua Chen; Hsin-Yi Chen; Kevin Bray; Anupama Reddy; Gyan Bhanot; Celine Gelinas; Robert S Dipaola; Vassiliki Karantza-Wadsworth; Eileen White
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

10.  Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling.

Authors:  Michal Caspi Tal; Miwa Sasai; Heung Kyu Lee; Brian Yordy; Gerald S Shadel; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

View more
  27 in total

Review 1.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

2.  Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.

Authors:  Ezgi Avsar Abdik; Hüseyin Abdik; Duygu Turan; Fikrettin Sahin; Martin R Berger; Ferda Kaleagasioglu
Journal:  Mol Biol Rep       Date:  2021-10-13       Impact factor: 2.316

3.  Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer.

Authors:  Daniel Eberli; Benedikt Kranzbühler; Lukas Prause; Valentin Baumgartner; Sheryl Preda; Rosa Sousa; Fabienne Lehner; Souzan Salemi
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-25       Impact factor: 4.322

4.  Signature for Prostate Cancer Based on Autophagy-Related Genes and a Nomogram for Quantitative Risk Stratification.

Authors:  Chenghao Wen; Qintao Ge; Bangshun Dai; Jiawei Li; Feixiang Yang; Jialin Meng; Shenglin Gao; Song Fan; Li Zhang
Journal:  Dis Markers       Date:  2022-07-07       Impact factor: 3.464

5.  Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.

Authors:  Quentin McAfee; Zhihui Zhang; Arabinda Samanta; Samuel M Levi; Xiao-Hong Ma; Shengfu Piao; John P Lynch; Takeshi Uehara; Antonia R Sepulveda; Lisa E Davis; Jeffrey D Winkler; Ravi K Amaravadi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

6.  USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination.

Authors:  Arishya Sharma; Turkeya Alswillah; Kamini Singh; Payel Chatterjee; Belinda Willard; Monica Venere; Matthew K Summers; Alexandru Almasan
Journal:  Autophagy       Date:  2018-08-10       Impact factor: 16.016

7.  Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells.

Authors:  Ling-Yen Chiu; Ming-E Hu; Tsung-Ying Yang; I-Lun Hsin; Jiunn-Liang Ko; Kan-Jen Tsai; Gwo-Tarng Sheu
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

8.  Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells.

Authors:  Xiaohong Pan; Xiuli Zhang; Hongliu Sun; Jinjin Zhang; Miaomiao Yan; Huaibin Zhang
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

9.  Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells.

Authors:  Xiaoshu Li; Jun Yan; Lisheng Wang; Fengjun Xiao; Yuefeng Yang; Xiaozhong Guo; Hua Wang
Journal:  Cancer Cell Int       Date:  2013-03-13       Impact factor: 5.722

10.  The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells.

Authors:  Jeong Yong Jeon; Seung Won Kim; Ki Cheong Park; Mijin Yun
Journal:  BMC Cancer       Date:  2015-09-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.